title: Recent advances for FLAP inhibitors.
abstract: A number of FLAP inhibitors have been progressed to clinical trials for respiratory and other inflammatory indications but so far no drug has reached the market. With this Digest we assess the opportunity to develop FLAP inhibitors for indications beyond respiratory disease, and in particular for atherosclerotic cardiovascular disease. We also show how recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP inhibitors paving the way for new compound classes.
authors.affiliation: CVMD iMed, AstraZeneca R&D Mölndal, S-413 83 Mölndal, Sweden. Electronic address: daniel.pettersen@astrazeneca.com.
authors.forename: Daniel
authors.initials: D
authors.lastname: Pettersen
authors.affiliation: CVMD iMed, AstraZeneca R&D Mölndal, S-413 83 Mölndal, Sweden.
authors.forename: Öjvind
authors.initials: Ö
authors.lastname: Davidsson
authors.affiliation: CVMD iMed, AstraZeneca R&D Mölndal, S-413 83 Mölndal, Sweden.
authors.forename: Carl
authors.initials: C
authors.lastname: Whatling
mesh_terms: D058946:5-Lipoxygenase-Activating Protein Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D050197:Atherosclerosis / Q000188:drug therapy; D015195:Drug Design; D055808:Drug Discovery; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D015289:Leukotrienes / Q000378:metabolism; D015394:Molecular Structure
chemical_list: D058946:5-Lipoxygenase-Activating Protein Inhibitors; D015289:Leukotrienes
keywords: 5-LO; Cardiovascular; FLAP; Inflammatory; Leukotrienes